Amedeo Smart

Free Medical Literature Service


 

Amedeo

Thoracic Surgery

  Free Subscription

Articles published in
Am Heart J
    June 2026
  1. CORTESE B, Mohammed AA, Malakouti S, Sivalingam J, et al
    Antiplatelet treatment after drug-coated balloon treatment: Review of the current evidence and future perspectives.
    Am Heart J. 2026;296:107361.
    >> Share

  2. LIAO W, Rashid M, Brookes CL, Barber S, et al
    Study design for an emulated trial of a 2 arm, parallel, stratified, adaptive, RCT of CABG versus PCI in people requiring myocardial revascularization at high risk (High-Risk REVASC).
    Am Heart J. 2026;296:107368.
    >> Share

    February 2026
  3. HEUTS S, Pustjens TFS, Lux A, Gabrio A, et al
    Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: a Bayesian re-analysis of the SLIM trial.
    Am Heart J. 2026 Feb 5:107369. doi: 10.1016/j.ahj.2026.107369.
    >> Share

  4. HILL KD, Koerner J, Hong H, Li JS, et al
    A Bayesian re-analysis of the STRESS trial.
    Am Heart J. 2026;292:107282.
    >> Share

    January 2026
  5. ARMSTRONG PW, Zheng Y, Welsh RC, Sinnaeve PR, et al
    Primary Percutaneous Coronary Intervention within the First Hour: Insights from Early-Treated Patients with ST-Elevation Myocardial Infarction.
    Am Heart J. 2026 Jan 29:107363. doi: 10.1016/j.ahj.2026.107363.
    >> Share

  6. WANG C, Liu Z, Li Z, Yan X, et al
    STrategies for Antithrombotic tRreatment following Transcatheter Edge-to-Edge Repair in patients with severe mitral regurgitation: rationale and design of STAR-TEER trial.
    Am Heart J. 2026 Jan 28:107362. doi: 10.1016/j.ahj.2026.107362.
    >> Share

  7. VEKSTEIN AM, Salah HM, Stebbins A, Wegermann Z, et al
    Early Outcomes of Off-Label Transcatheter Tricuspid Valve Repair/Replacement in the STS/ACC TVT Registry.
    Am Heart J. 2026 Jan 19:107355. doi: 10.1016/j.ahj.2026.107355.
    >> Share

  8. MAYOURIAN J, Sleeper LA, Diwanji V, Geva A, et al
    Artificial intelligence-enabled electrocardiogram guidance for pulmonary valve replacement timing in repaired tetralogy of Fallot.
    Am Heart J. 2026;291:153-161.
    >> Share

  9. SHAH AH, Armstrong HK, Mittal I, Reimer A, et al
    IMpact of therapY using coleSevelam treatment reducing bile acids in patients with fonTan cIrCulation (MYSTIC): Rationale and study design.
    Am Heart J. 2026;291:81-88.
    >> Share

    December 2025
  10. D'ENTREMONT MA, Lee SF, Wijeysundera HC, Tsang MB, et al
    Design and Rationale of the HD PCI Trial: A Cluster Randomized Crossover Trial of Higher vs. Lower Dose Heparin for Elective Percutaneous Coronary Intervention.
    Am Heart J. 2025 Dec 22:107330. doi: 10.1016/j.ahj.2025.107330.
    >> Share

  11. HARVEY JE 3RD, Ryan M, Gunnarsson C, Chikermane S, et al
    Incremental cost of complications after TAVR and SAVR in contemporary clinical practice.
    Am Heart J. 2025;290:278-287.
    >> Share

  12. ALSAIED T, Li R, Grant H, Schiff MD, et al
    Defining diastolic dysfunction post-Fontan: Threshold, risk factors, and associations with outcomes.
    Am Heart J. 2025;290:288-296.
    >> Share

  13. ABDELHALIM AT, Reddy YVN, Miranda WR, Kamath PS, et al
    Prognostic value of liver biomarker scores for risk stratification in adults with Fontan palliation.
    Am Heart J. 2025;290:170-179.
    >> Share

  14. LI Y, Schiff M, Olivieri LJ, Christopher AB, et al
    The long-term effect of the Fontan fenestration on clinical outcomes: A FORCE registry study.
    Am Heart J. 2025;290:105-114.
    >> Share

  15. GALLEGOS FN, Bernstein D, Punn R, Long J, et al
    Systolic performance of the single ventricle, exercise capacity, and endothelial function in pediatric Fontan patients.
    Am Heart J. 2025;290:58-68.
    >> Share

  16. WEI C, Sharma P, Paranjpe I, Heidenreich PA, et al
    Balancing cost and care: Analyzing commercial pricing for TAVR and SAVR.
    Am Heart J. 2025;290:1-5.
    >> Share

    November 2025
  17. SHAN J, Gao J, Chen Y, Ji H, et al
    Efficacy and Safety of Postoperative Autologous Blood Transfusion in Cardiac Surgery (RESCUE): Rationale, Design, and Study Protocol of a Multicenter Randomized Controlled Trial.
    Am Heart J. 2025 Nov 27:107313. doi: 10.1016/j.ahj.2025.107313.
    >> Share

  18. MAGOD BL, Hughes ZH, Manjunath A, Wu T, et al
    Incidence and risk factors for malignancy after heart transplantation- Analysis of the UNOS Registry.
    Am Heart J. 2025 Nov 21:107308. doi: 10.1016/j.ahj.2025.107308.
    >> Share

  19. LI J, Wang ZY, Yan J, Li WH, et al
    Prospective, multicenter, randomized controlled study on the efficacy and safety of intravascular ultrasound-guided drug-coated balloon for de novo small-vessel coronary lesions: Design and rationale of the DCB-IVUS trial.
    Am Heart J. 2025 Nov 18:107307. doi: 10.1016/j.ahj.2025.107307.
    >> Share

  20. VAN DEN ENDEN AJM, van den Dorpel MMP, Mondellini GM, Mattace-Raso AM, et al
    Immediate changes in Left Ventricular Cardiac Mechanics following Transcatheter Aortic Valve Replacement for Severe Aortic Stenosis - an In-Vivo Pressure-Volume Analysis study.
    Am Heart J. 2025 Nov 13:107302. doi: 10.1016/j.ahj.2025.107302.
    >> Share

  21. MONTALESCOT G, Bolognese L, Bartus S, Cequier-Fillat A, et al
    Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: Design of the AMUNDSEN Trial.
    Am Heart J. 2025 Nov 3:107295. doi: 10.1016/j.ahj.2025.107295.
    >> Share

  22. TOBE A, van Royen N, Amat-Santos IJ, Hudec M, et al
    Win ratio analysis of the LANDMARK trial.
    Am Heart J. 2025;289:1-5.
    >> Share

    October 2025
  23. HEMELRIJK K, Jimenez-Diaz VA, Vilchez JP, Oteo JF, et al
    Rationale and design of REAC-TAVI 2: single antiplatelet treatment with ticagrelor versus aspirin after transcatheter aortic valve implantation.
    Am Heart J. 2025 Oct 31:107293. doi: 10.1016/j.ahj.2025.107293.
    >> Share

  24. OVERDUIN DC, van Ginkel DJ, Dubois C, Lesizza P, et al
    Routine versus selective protamine administration to reduce bleeding after TAVI: Rationale and Design of the POPular ACE TAVI trial.
    Am Heart J. 2025 Oct 31:107296. doi: 10.1016/j.ahj.2025.107296.
    >> Share

  25. IGLESIAS JF, Leibundgut G, Heg D, Gasparini GL, et al
    Distal versus conventional radial large-bore access for percutaneous coronary intervention of complex coronary lesions: Rationale and design of the DISCO COMPLEX randomized superiority trial.
    Am Heart J. 2025 Oct 18:107291. doi: 10.1016/j.ahj.2025.107291.
    >> Share

  26. ABDELAZIZ A, Ramadan S, Hasan MT, Desouky M, et al
    Complete Revascularization in Patients with Acute Myocardial Infarction and Multivessel Disease: Pooled Analysis of Kaplan-Meier-Derived Individual-Patient-Data.
    Am Heart J. 2025 Oct 2:107284. doi: 10.1016/j.ahj.2025.107284.
    >> Share

  27. KIM KS, Belley-Cote EP, Walsh M, Wang A, et al
    Left atrial appendage occlusion study III-Kidney substudy.
    Am Heart J. 2025;288:90-100.
    >> Share

    September 2025
  28. TOMII D, Alaour B, Heg D, Okuno T, et al
    Self-Expanding Versus Balloon-Expandable Transcatheter Heart Valves in Patients with Excessive Aortic Valve Cusp Calcification.
    Am Heart J. 2025 Sep 18:S0002-8703(25)00333-3. doi: 10.1016/j.ahj.2025.
    >> Share

  29. LANDMESSER U, Skurk C, Kirchhof P, Lewalter T, et al
    Catheter-based left atrial appendage CLOSURE in patients with Atrial Fibrillation at high risk of stroke and bleeding as compared to best medical therapy: Rationale and design of the prospective randomized CLOSURE-AF trial.
    Am Heart J. 2025 Sep 12:S0002-8703(25)00326-6. doi: 10.1016/j.ahj.2025.
    >> Share

  30. FEISTRITZER HJ, Jobs A, Zeymer U, Schneider S, et al
    Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease - Design and rationale of the randomized COMPLETE-NSTEMI trial.
    Am Heart J. 2025;287:94-106.
    >> Share

    August 2025
  31. HOLMEN S, Manintveld O, Damman K, Braun O, et al
    DAPAgliflozin for Renal protection in Heart Transplant recipients. Rationale and design of the randomized controlled DAPARHT trial.
    Am Heart J. 2025 Aug 19:S0002-8703(25)00300-X. doi: 10.1016/j.ahj.2025.
    >> Share

  32. PARK HS, Suh CH, Ahn JM, Kang DY, et al
    Effect of Cerebral Embolic Protection Device on New Cerebral Embolism During Transcatheter Aortic Valve Replacement: A Prospective Sentinel Registry.
    Am Heart J. 2025 Aug 13:S0002-8703(25)00296-0. doi: 10.1016/j.ahj.2025.
    >> Share

    July 2025
  33. JORGENSEN TH, Thyregod HGH, Blankenberg S, Leon M, et al
    The Low-Risk TAVR Trials - A Critical Appraisal of the Current Landscape.
    Am Heart J. 2025 Jul 29:S0002-8703(25)00288-1. doi: 10.1016/j.ahj.2025.
    >> Share

  34. VAKILPOUR A, Levin MG, Anyanwu EC, Denduluri S, et al
    Referral patterns and clinical outcomes in patients with severe aortic stenosis: A multicenter cohort study.
    Am Heart J. 2025 Jul 22:S0002-8703(25)00223-6. doi: 10.1016/j.ahj.2025.
    >> Share

  35. HAN M, Kang J, Kim B, Hwang D, et al
    The impact of body mass index (BMI) on antiplatelet monotherapy strategy for secondary prevention after percutaneous coronary intervention: A sub-study of the HOST-EXAM trial.
    Am Heart J. 2025 Jul 5:S0002-8703(25)00214-5. doi: 10.1016/j.ahj.2025.
    >> Share

  36. PITARO N, Nicolas J, Sartori S, Shneyderman M, et al
    Impact of Left Ventricular Function on Outcomes in Patients with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2025 Jul 1:S0002-8703(25)00203-0. doi: 10.1016/j.ahj.2025.
    >> Share

    June 2025
  37. KRASNIQI L, Skovbo JS, Hallas PJ, Brandes PA, et al
    Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.
    Am Heart J. 2025 Jun 13:S0002-8703(25)00194-2. doi: 10.1016/j.ahj.2025.
    >> Share

  38. CUTLIP DE, Mehran R, Doros G, Kaplinskiy V, et al
    Prospective randomized single-blind multicenter study to assess the safety and effectiveness of the SELUTION SLR 014 drug eluting balloon in the treatment of subjects with in-stent restenosis: Rationale and design.
    Am Heart J. 2025;284:11-19.
    >> Share

    May 2025
  39. MAINI AS, Abu-Much A, Redfors B, Wollmuth JR, et al
    Outcomes Among Patients with Coronary Bifurcation Lesions Undergoing Impella-Supported High-Risk Percutaneous Coronary Intervention.
    Am Heart J. 2025 May 22:S0002-8703(25)00176-0. doi: 10.1016/j.ahj.2025.
    >> Share

  40. WHITE HD, O'Brien SM, Boden WE, Fremes SE, et al
    Use of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention and Associated Outcomes in the ISCHEMIA Trial.
    Am Heart J. 2025 May 20:S0002-8703(25)00165-6. doi: 10.1016/j.ahj.2025.
    >> Share

  41. GOLD ME, Kulkarni S, Yadalam A, Patel KJ, et al
    Cardiac Allograft Vasculopathy Mediates the Relationship Between Vitamin D Deficiency and Cardiovascular Mortality Following Heart Transplantation.
    Am Heart J. 2025 May 16:S0002-8703(25)00166-8. doi: 10.1016/j.ahj.2025.
    >> Share

  42. MESSINGER MC, Ashburn NP, Chait JS, Snavely AC, et al
    Risk of delayed percutaneous coronary intervention for STEMI in the Southeast United States.
    Am Heart J. 2025 May 13:S0002-8703(25)00157-7. doi: 10.1016/j.ahj.2025.
    >> Share

  43. KANDZARI DE, Latib A, Mylotte D, Ali ZA, et al
    Rationale and design of the prevail global trial program evaluating the prevail drug-coated balloon in patients with in-stent restenosis and de novo small vessel disease.
    Am Heart J. 2025;283:26-36.
    >> Share

    April 2025
  44. JIANG Z, Chang S, Tao L, Luo J, et al
    The randomized controlled trial to compare temporary permanent pacemaker versus temporary pacemaker in patients with conduction block after transcatheter aortic valve replacement: rationale and design of the RECOVER trial: Randomized trial for Tempora
    Am Heart J. 2025 Apr 19:S0002-8703(25)00135-8. doi: 10.1016/j.ahj.2025.
    >> Share

  45. GOSVIG K, Goller J, Hansson NH, Brandes A, et al
    Rationale and design of the Anticoagulant Therapy after Left Atrial Appendage Closure (ATLAAC) Trial.
    Am Heart J. 2025 Apr 15:S0002-8703(25)00131-0. doi: 10.1016/j.ahj.2025.
    >> Share

  46. HAKEEM A, Ali Shah J, Kumar R, Khan K, et al
    Rationale and Design of the TADCLOT Trial: A Double Blind Randomized Controlled Trial Comparing Twice a Day Clopidogrel vs. Ticagrelor in Reducing Major Cardiac Events in Patients with Acute STEMI Undergoing Primary Percutaneous Coronary Intervention.
    Am Heart J. 2025 Apr 12:S0002-8703(25)00103-6. doi: 10.1016/j.ahj.2025.
    >> Share

  47. SOMSEN YBO, de Winter RW, Wu J, Hoek R, et al
    Design and rationale of the drug-coated balloon coronary angioplasty versus stenting for treatment of disease adjacent to a chronic total occlusion (Co-CTO) trial.
    Am Heart J. 2025 Apr 7:S0002-8703(25)00105-X. doi: 10.1016/j.ahj.2025.
    >> Share

  48. HORN N, Gartner L, Rastan AJ, Andrasi TB, et al
    Effects of a preoperative psychological expectation-focused intervention in patients undergoing valvular surgery - the randomized controlled ValvEx (valve patients' expectations) study.
    Am Heart J. 2025;282:156-169.
    >> Share

  49. HSU AR, Karnakoti S, Abdelhalim AT, Miranda WR, et al
    Incidence and outcomes of prosthetic valve endocarditis in adults with congenital heart disease.
    Am Heart J. 2025;282:125-133.
    >> Share

    February 2025
  50. AUER J, Lamm G
    High-risk features and probability of ischemic and bleeding events after percutaneous coronary intervention.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00058-4. doi: 10.1016/j.ahj.2025.
    >> Share

  51. ANDO T, Nazif T, Briasoulis A, Afonso L, et al
    Clinical Outcomes of Direct Oral Anticoagulant Versus Warfarin After Transcatheter Aortic Valve Replacement: From the STS/ACC TVT Registry.
    Am Heart J. 2025 Feb 26:S0002-8703(25)00057-2. doi: 10.1016/j.ahj.2025.
    >> Share

  52. ERRIQUEZ A, Colaiori I, Hakeem A, Guiducci V, et al
    Functional Coronary Angiography to Indicate and Guide Revascularization in STEMI Patients with Multivessel Disease: Rationale and Design of the AIR-STEMI trial: Functional coronary angiography in STEMI patients.
    Am Heart J. 2025 Feb 19:S0002-8703(25)00042-0. doi: 10.1016/j.ahj.2025.
    >> Share

  53. JORGENSEN TH, Thyregod HGH, Savontaus M, Bleie O, et al
    Transcatheter or Surgical Aortic Valve Replacement in patients with Severe Aortic Stenosis Aged 70 Years or Younger - a NOTION-2 sub-study.
    Am Heart J. 2025 Feb 12:S0002-8703(25)00034-1. doi: 10.1016/j.ahj.2025.
    >> Share

  54. GAO XF, Kan J, Wu HY, Chen J, et al
    Intravascular Imaging-guided versus Angiography-guided Percutaneous Coronary Intervention in Patients with Diabetes Mellitus: Rationale and design of an International, Multicenter, Randomized IVI-DIABETES Trial.
    Am Heart J. 2025 Feb 4:S0002-8703(25)00017-1. doi: 10.1016/j.ahj.2025.
    >> Share

  55. WANG G, Zhang R, Chen SL, Wang J, et al
    Targeted Therapy with a Localized abluminal Groove Low-Dose Sirolimus-Eluting Bioabsorbable Polymer Coronary Stent in Chronic Total Occlusions: The TARGET CTO Non-Inferiority Randomized Trial.
    Am Heart J. 2025 Feb 3:S0002-8703(25)00018-3. doi: 10.1016/j.ahj.2025.
    >> Share

  56. NAKASE M, Tomii D, Maznyczka A, Heg D, et al
    Five-year outcomes with self-expanding versus balloon-expandable TAVI in patients with left ventricular systolic dysfunction.
    Am Heart J. 2025;280:18-29.
    >> Share

    January 2025
  57. BALDI C, Maio MD, Esposito L, Bellino M, et al
    How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry.
    Am Heart J. 2025 Jan 27:S0002-8703(25)00011-0. doi: 10.1016/j.ahj.2025.
    >> Share

  58. EFTEKHARI A, Christiansen EH, Lassen JF, Raungaard B, et al
    Randomized comparison of the combined Sirolimus eluting and endothelial progenitor cell Combo(TM) stent vs. Biolimus eluting absorbable polymer coated BioMatrix Alpha(TM) stent in patients undergoing percutaneous coronary intervention. Rationale and s
    Am Heart J. 2025 Jan 25:S0002-8703(25)00013-4. doi: 10.1016/j.ahj.2025.
    >> Share

  59. VELDTMAN GR, Abualsaud A, Cohen S, Ordonez MV, et al
    Fontan circulation and systemic disease - a retrospective cohort analysis over 35 years of follow-up.
    Am Heart J. 2025;279:40-49.
    >> Share

    December 2024
  60. CASSESE S, Simonetti F, Covarrubias HAA, Janisch M, et al
    Intracoronary Stenting and Additional Results Achieved by ShockWAVE Coronary Lithotripsy: Design and Rationale of ISAR-WAVE Trial.
    Am Heart J. 2024 Dec 20:S0002-8703(24)00337-5. doi: 10.1016/j.ahj.2024.
    >> Share

  61. POLLACK LM, Chang A, Thompson MP, Keteyian SJ, et al
    Hospital-level variation in cardiac rehabilitation metrics.
    Am Heart J. 2024 Dec 13:S0002-8703(24)00333-8. doi: 10.1016/j.ahj.2024.
    >> Share

  62. AARTS HM, Hemelrijk KI, Broeze GM, van Ginkel DJ, et al
    Deferral of routine percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation: rationale and design of the PRO-TAVI trial: the PRO-TAVI trial: rationale and design.
    Am Heart J. 2024 Dec 12:S0002-8703(24)00332-6. doi: 10.1016/j.ahj.2024.
    >> Share

    November 2024
  63. REDDY KP, Shultz K, Eberly LA, Khatana SAM, et al
    Contribution margins and utilization of transcatheter aortic valve replacement versus surgical aortic valve replacement in the Medicare population.
    Am Heart J. 2024 Nov 27:S0002-8703(24)00302-8. doi: 10.1016/j.ahj.2024.
    >> Share

  64. ABRAHAM B, Suppah M, Farina J, Botros M, et al
    Impact of Moderate or Severe Mitral and Tricuspid Valves Regurgitation after Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Nov 12:S0002-8703(24)00295-3. doi: 10.1016/j.ahj.2024.
    >> Share

  65. IANNOPOLLO G, Cocco M, Leone A, Sacca S, et al
    TRanscatheter Aortic-Valve Implantation with or without on-site Cardiac Surgery: the TRACS trial: TAVI in centers without on-site cardiac surgery.
    Am Heart J. 2024 Nov 4:S0002-8703(24)00281-3. doi: 10.1016/j.ahj.2024.
    >> Share

    October 2024
  66. BARONE-ROCHETTE G, Vanzetto G, Danchin N, Steg PG, et al
    Rationale and design of the multicentric randomized EVAOLD trial: evaluation of a strategy guided by imaging versus routine invasive strategy in elderly patients with ischemia.
    Am Heart J. 2024 Oct 22:S0002-8703(24)00274-6. doi: 10.1016/j.ahj.2024.
    >> Share

  67. WHITLOCK RP, McCarthy PM, Gerdisch MW, Ramlawi B, et al
    The left atrial appendage exclusion for prophylactic stroke reduction (leaaps) trial: rationale and design.
    Am Heart J. 2024 Oct 10:S0002-8703(24)00268-0. doi: 10.1016/j.ahj.2024.
    >> Share

  68. THURAIAIYAH J, Jorgensen TH, Jensen JM, Fuchs A, et al
    Prospective study on the impact of different anti-thrombotic therapies on subclinical leaflet thickening and its temporal dynamics in transcatheter aortic valves - The NOTION-4 trial: Anti-thrombotic therapy and TAV-HALT.
    Am Heart J. 2024 Oct 5:S0002-8703(24)00264-3. doi: 10.1016/j.ahj.2024.
    >> Share

    September 2024
  69. DE COCK E, Kautbally S, Timmermans F, Bogaerts K, et al
    Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: rationale and design of the COL BE PCI trial: Short title: Rationale and design of the COL BE PCI trial.
    Am Heart J. 2024 Sep 2:S0002-8703(24)00225-4. doi: 10.1016/j.ahj.2024.
    >> Share

  70. GATTI G, Fiore A, Ismail M, Dralov A, et al
    Prediction of 30-day mortality after surgery for infective endocarditis using risk scores: Insights from a European multicenter comparative validation study.
    Am Heart J. 2024;275:108-118.
    >> Share

    August 2024
  71. DISMORR M, Granbom-Koski M, Ellfors E, Ruck A, et al
    Sex differences and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Aug 9:S0002-8703(24)00185-6. doi: 10.1016/j.ahj.2024.
    >> Share

  72. STAHLI BE, Linke A, Westermann D, Van Mieghem NM, et al
    A Randomized Comparison of the Treatment Sequence of Percutaneous Coronary Intervention and Transcatheter Aortic Valve Implantation: Rationale and Design of the TAVI PCI Trial.
    Am Heart J. 2024 Aug 7:S0002-8703(24)00184-4. doi: 10.1016/j.ahj.2024.
    >> Share

  73. MEDINA CK, Barnes SG, Felker GM, Mentz RJ, et al
    Severe obesity among patients with left ventricular assist devices.
    Am Heart J. 2024;274:130-133.
    >> Share

  74. TERKELSEN CJ, Thim T, Freeman P, Dahl JS, et al
    Randomized comparison of TAVI valves: The Compare-TAVI trial.
    Am Heart J. 2024;274:84-94.
    >> Share

  75. DUARTE VE, Yamamura K, Economy KE, Graf JA, et al
    The effects of pregnancy in subjects with repaired tetralogy of Fallot.
    Am Heart J. 2024;274:95-101.
    >> Share

    July 2024
  76. BUTT JH, Yafasova A, Thein D, Begun X, et al
    Burden of Hospitalization During the First Year Following Transcatheter and Surgical Aortic Valve Replacement.
    Am Heart J. 2024 Jul 29:S0002-8703(24)00180-7. doi: 10.1016/j.ahj.2024.
    >> Share

  77. ERBAY A, Penzel L, Abdelwahed YS, Heuberger A, et al
    Prognostic impact of quantitative flow ratio (QFR)-consistent complete revascularization in patients with myocardial infarction and multivessel coronary artery disease.
    Am Heart J. 2024 Jul 19:S0002-8703(24)00177-7. doi: 10.1016/j.ahj.2024.
    >> Share

  78. ELLFORS E, Dismorr M, Ruck A, Settergren M, et al
    Predicted prosthesis-patient mismatch and long-term clinical outcomes after transcatheter aortic valve replacement: a SWEDEHEART study.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00175-3. doi: 10.1016/j.ahj.2024.
    >> Share

  79. PERSITS I, Mirzai S, Sarnaik KS, Volk MC, et al
    Sarcopenia and Frailty in Patients Undergoing Transcatheter Aortic Valve Replacement.
    Am Heart J. 2024 Jul 18:S0002-8703(24)00173-X. doi: 10.1016/j.ahj.2024.
    >> Share

  80. POLSINELLI VB, Koczo A, Johnson AE, Elkayam U, et al
    Race, Hypertensive Disorders of Pregnancy and Outcomes in Peripartum Cardiomyopathy.
    Am Heart J. 2024 Jul 10:S0002-8703(24)00168-6. doi: 10.1016/j.ahj.2024.
    >> Share

  81. YANG Y, Chu TC, Suthar D, Beshish AG, et al
    Association of patient-level characteristics with long-term outcomes after Fontan palliation: Rationale, design, and baseline characteristics of the Pediatric Cardiac Care Consortium Fontan cohort study.
    Am Heart J. 2024;273:111-120.
    >> Share

    June 2024
  82. ABOU-KARAM R, Tanguturi V, Cheng F, Elmariah S, et al
    Trial Designs A44002PZS Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: Rationale, design, and methods of the randomized controlled DETECT AS Trial.
    Am Heart J. 2024 Jun 29:S0002-8703(24)00163-7. doi: 10.1016/j.ahj.2024.
    >> Share

  83. WU ZM, Kan J, Ye F, You W, et al
    PCSK9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: A Randomized, Double- Blind, Placebo-Controlled, Multicenter SHAWN Study.
    Am Heart J. 2024 Jun 26:S0002-8703(24)00157-1. doi: 10.1016/j.ahj.2024.
    >> Share

  84. MIYAWAKI N, Ishizu K, Shirai S, Miyahara K, et al
    Impact of the Clinical Frailty Scale on Long-term Outcomes After Transcatheter Aortic Valve Implantation.
    Am Heart J. 2024 Jun 12:S0002-8703(24)00139-X. doi: 10.1016/j.ahj.2024.
    >> Share

  85. BRUNO F, Rampone JM, Islas F, Gorla R, et al
    Echocardiographic and clinical features of patients developing prosthesis-patient mismatch after TAVR: insights from the Recovery TAVR registry.
    Am Heart J. 2024 Jun 3:S0002-8703(24)00137-6. doi: 10.1016/j.ahj.2024.
    >> Share

    May 2024
  86. RICHARDSON C, Gilbert T, Aslam S, Brookes CL, et al
    Rationale and design of the Early valve replacement in severe ASYmptomatic Aortic Stenosis Trial.
    Am Heart J. 2024 May 29:S0002-8703(24)00128-5. doi: 10.1016/j.ahj.2024.
    >> Share

  87. LUPU L, Haberman D, Chitturi KR, Wermers JP, et al
    Overview of 2024 FDA Advisory Panel Meeting on the TriClip Transcatheter Tricuspid Valve Repair System.
    Am Heart J. 2024 May 29:S0002-8703(24)00126-1. doi: 10.1016/j.ahj.2024.
    >> Share

  88. KIM Y, Park H, Yoon HJ, Suh J, et al
    Fully Automated Quantitative Coronary Angiography Versus Optical Coherence Tomography Guidance for Coronary Stent Implantation (FLASH): Study Protocol for a Randomized Controlled Non-Inferiority Trial.
    Am Heart J. 2024 May 7:S0002-8703(24)00119-4. doi: 10.1016/j.ahj.2024.
    >> Share

  89. ZHANG F, Tian M, Wang X, Zhang H, et al
    Rationale and design of a Single-center Randomized Trial to Compare the Graft Patency between the Radial Artery and the No-touch Saphenous Vein in Coronary Artery Bypass Grafting Surgery (GRAFT-CAB Study).
    Am Heart J. 2024 May 4:S0002-8703(24)00117-0. doi: 10.1016/j.ahj.2024.
    >> Share

  90. LEMLEY BA, Okunowo O, Ampah SB, Wu L, et al
    Effect of patient factors, center, and era on Fontan timing: An observational study using the Pediatric Health Information Systems Database.
    Am Heart J. 2024;271:156-163.
    >> Share

  91. GUO Y, Liu X, Li R, Ng S, et al
    Comparison of Down Sizing Strategy (HANGZHOU Solution) and Standard Annulus Sizing Strategy in type 0 bicuspid aortic stenosis patients undergoing transcatheter aortic valve replacement: Rationale and design of a randomized clinical trial.
    Am Heart J. 2024 May 1:S0002-8703(24)00098-X. doi: 10.1016/j.ahj.2024.
    >> Share

    April 2024
  92. KIM MC, Ahn JH, Hyun DY, Lim Y, et al
    Timing of fractional flow reserve-guided complete revascularization in patients with ST-segment elevation myocardial infarction with multivessel disease: Rationale and design of the OPTION-STEMI trial.
    Am Heart J. 2024 Apr 17:S0002-8703(24)00078-4. doi: 10.1016/j.ahj.2024.
    >> Share

  93. ETIWY M, Flannery LD, Li SX, Morrison FJ, et al
    Examining Lack of Referrals to Heart Valve Specialists as Mechanisms of Potential Underutilization of Aortic Valve Replacement.
    Am Heart J. 2024 Apr 13:S0002-8703(24)00093-0. doi: 10.1016/j.ahj.2024.
    >> Share

    March 2024
  94. GUINOT PG, Desebbe O, Besch G, Guerci P, et al
    Prospective randomized double-blind study to evaluate the superiority of Vasopressin versus Norepinephrine in the management of the patient at renal risk undergoing cardiac surgery with cardiopulmonary bypass (NOVACC trial).
    Am Heart J. 2024 Mar 14:S0002-8703(24)00068-1. doi: 10.1016/j.ahj.2024.
    >> Share

  95. KRUCOFF M, Spirito A, Baber U, Sartori S, et al
    Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: a subgroup analysis of the TWILIGHT randomized clinical trial.
    Am Heart J. 2024 Mar 6:S0002-8703(24)00053-X. doi: 10.1016/j.ahj.2024.
    >> Share

  96. DOU D, Yuan S, Jia Y, Wang Y, et al
    The protocol of enhanced recovery after cardiac surgery in adult patients: a stepped wedge cluster randomized trial.
    Am Heart J. 2024 Mar 2:S0002-8703(24)00051-6. doi: 10.1016/j.ahj.2024.
    >> Share

    February 2024
  97. ZHANG J, Kong XQ, Gao XF, Chen J, et al
    Transfemoral transcatheter aortic valve replacement with VitaFlow(TM) valve for pure native aortic regurgitation in patients with high surgical risk: Rationale and design of a prospective, multicenter, and randomized SEASON-AR trial.
    Am Heart J. 2024 Feb 25:S0002-8703(24)00049-8. doi: 10.1016/j.ahj.2024.
    >> Share

    January 2024
  98. JAMMOUL N, Dupasquier V, Akodad M, Meunier PA, et al
    Long-term follow-up of balloon-expandable valves according to the implantation strategy: insight from the DIRECTAVI trial.
    Am Heart J. 2024 Jan 20:S0002-8703(24)00014-0. doi: 10.1016/j.ahj.2024.
    >> Share

    September 2023
  99. ATALLAH J, Chiha T, Chen C, Siller-Matula JM, et al
    Clinical outcomes associated with type II myocardial infarction caused by bleeding.
    Am Heart J. 2023;263:85-92.
    >> Share

    August 2023
  100. DODGSON CAS, Beitnes JO, Klove SF, Herstad J, et al
    An investigator-sponsored pragmatic randomised controlled trial of AntiCoagulation versus AcetylSalicylic Acid after Transcatheter Aortic Valve Implantation - Rationale and design of ACASA-TAVI: Blinded outcome adjudication.
    Am Heart J. 2023 Aug 25:S0002-8703(23)00208-9. doi: 10.1016/j.ahj.2023.
    >> Share

    July 2023
  101. KALMUCKI P, Lipiecki J, Witte KK, Goldberg SL, et al
    Percutaneous mitral annuloplasty with the Carillon device: outcomes in proportionate and disproportionate functional mitral regurgitation.
    Am Heart J. 2023 Jul 27:S0002-8703(23)00181-3. doi: 10.1016/j.ahj.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016